Heiko Becker

University of Freiburg — Germany

Medicine · Health Sciences

40h-index7.9kcitations182works1.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(108), Chronic Myeloid Leukemia Treatments(45), Myeloproliferative Neoplasms: Diagnosis and Treatment(42), Histone Deacetylase Inhibitors Research(18), Cancer Genomics and Diagnostics(17)

Publications182 total

Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort
Frontiers in Oncology·2025Open Access
A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006
Blood·2025Open Access
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Blood·2025
Response to PD-1 inhibition in MMRd/MSS pancreatic ductal adenocarcinoma: the relevance of parallel testing
Journal of Cancer Research and Clinical Oncology·2025Open Access
Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial
Leukemia·2025· 1 citedOpen Access
All-trans Retinsäure und Arsentrioxid verbessern die Wirksamkeit von Gemcitabin im PDAC: Funktionelle Validierung im Organoidmodell und Analyse klinischer Biomarker
Zeitschrift für Gastroenterologie·2025
Molecular tumor board-guided personalized therapies in biliary tract cancer: a real-world analysis
Zeitschrift für Gastroenterologie·2025
Neoadjuvante Checkpointinhibition bei Kolonkarzinomen mit Mismatch-Repair-Defizienz/Mikrosatelliteninstabilität im Real-World-Setting
Zeitschrift für Gastroenterologie·2025
Improving outcomes in gyneco-oncology in late and last line setting: Real-world data from the molecular tumor board registry trial at the Comprehensive Cancer Center Freiburg (Germany).
Journal of Clinical Oncology·2025· 1 cited
Combined RAF- and MEK-inhibition in solid cancers with kinase-impaired BRAF mutations (SORATRAM phase I trial).
Journal of Clinical Oncology·2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
Blood Advances·2025Open Access
Abstract 4705: FreezeO organoid biobank: A translational pipeline for precision oncology at the University Medical Center Freiburg
Cancer Research·2025
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
HemaSphere·2025· 1 citedOpen Access
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Leukemia·2025· 9 citedOpen Access
Intraindividual Comparison of Recognition of Symptom Burden in MPN between Patient- and Physician-Reported Assessment and Its Impact on Survival - an Analysis By the German Study Group for MPN (GSG-MPN)
Blood·2024· 2 citedOpen Access
Impact of <i>TP53</i> Mutation Status in Elderly <scp>AML</scp> Patients When Adding All‐<i>Trans</i> Retinoic Acid or Valproic Acid to Decitabine
European Journal Of Haematology·2024· 5 citedOpen Access
DNMT3A CHIP-driver mutations ignite the bone marrow
European Heart Journal·2024Open Access
Supplementary Data from Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
2024Open Access
Data from Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
2024Open Access
Supplementary Data from Oncogenic Calreticulin Induces Immune Escape by Stimulating TGFβ Expression and Regulatory T-cell Expansion in the Bone Marrow Microenvironment
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Guido Marcucci(24), Sebastian Schwind(24), Krzysztof Mrózek(22), Susan P. Whitman(22), Clara D. Bloomfield(21), Jonathan E. Kolitz(20), Michael A. Caligiuri(20), Klaus H. Metzeler(19), Bayard L. Powell(18), Maria R. Baer(18), Kati Maharry(17), Andrew J. Carroll(17), Thomas H. Carter(15), Richard A. Larson(15), Yue-Zhong Wu(14), Michael D. Radmacher(14), Deedra Nicolet(14), Jessica Kohlschmidt(13), Meir Wetzler(12), Joseph O. Moore(10)